Portfolio

EditForce developed a unique DNA/RNA editing technology, based on a pentatricopeptide repeat (PPR) protein platform technology, which has a distinct feature that enables the editing of not only DNA but also RNA, highlighting its difference compared to other technologies. It has different mechanisms to work and isolated intellectual property from other existing DNA/RNA editing technologies. RNA editing technology could be an intervention to treat diseases derived from RNA splicing abnormality and abnormal repeat-RNA sequence, or diseases known to result from mutations susceptible to cure by single base editing technology, which PPR could achieve. The platform technology is expected to be applied to a wide range of fields.